Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_205_библиотеки_им_акад_М_И_Перельмана
.pdf
xx The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Lisa A. O’Donnell, Ph.D.
Assistant Professor, Wayne State University, Detroit, Michigan
Dan A. Oren, M.D.
Associate Professor of Psychiatry (Adjunct), Yale University, New Haven, Connecticut
Vanessa Padilla, M.D.
Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of
Miami Leonard Miller School of Medicine, Miami, Florida
Carmine Maria Pariante, M.D., Ph.D., FRCPsych
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London; National Institute for Health and Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and
King’s College London, London, United Kingdom
Brenda W.J. H. Penninx, M.D., Ph.D.
Professor of Psychiatric Epidemiology, Department of Psychiatry, Amsterdam Neuroscience and Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije
Universiteit, Amsterdam, The Netherlands
Mary L. Phillips, M.D., M.D. (Cantab)
Pittsburgh Foundation–Emmerling Endowed Chair in Psychotic Disorders and Professor in Psychiatry and Clinical and Translational Science; Director of Center for
Translational and Developmental Affective Neuroscience, Collaborative on Mood Disorders Research, and Mood and Brain Laboratory; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Grazyna Rajkowska, Ph.D.
Professor, Department of Psychiatry and Human Behavior, University of Mississippi
Medical Center, Jackson, Mississippi
Natalie Rasgon, M.D., Ph.D.
Professor, Departments of Psychiatry and Behavioral Sciences and Obstetrics & Gynecology, Stanford University School of Medicine, Stanford, California; Director of the
Stanford Center for Neuroscience in Women’s Health; Associate Dean of Academic
Affairs
Darrel A. Regier, M.D., M.P.H.
Adjunct Professor in Psychiatry, Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Senior Scientist, Center for the
Study of Traumatic Stress, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland
Mina M. Rizk, M.B.B.Ch., M.Sc.
Postgraduate Year 1, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York; Postdoctoral Fellow, Research Foundation for Mental Hygiene, New York State Psychiatric Institute, New York, New York
Norman E. Rosenthal, M.D.
Clinical Professor of Psychiatry, Georgetown University Medical School, Washington,
DC
xxi Contributors
https://t.me/med1917
Mitchell Rovner, M.D.
Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of
Miami Leonard Miller School of Medicine, Miami, Florida
Eric Rubin, M.D., Ph.D.
Associate Clinical Professor of Psychiatry, Columbia University College of Physicians
and Surgeons, Harlem Hospital, New York, New York
James K. Rustad, M.D.
Psychiatrist, Department of Mental Health and Behavioral Sciences, White River Junction VA Medical Center, White River Junction, Vermont; Assistant Professor of Psychiatry, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon,
New Hampshire
Gerard Sanacora, M.D., Ph.D.
Professor of Psychiatry, Yale University, New Haven, Connecticut
Alan F. Schatzberg, M.D.
Kenneth T. Norris Jr. Professor, Department of Psychiatry and Behavioral Sciences,
Stanford University School of Medicine, Stanford, California; Director, Stanford Mood
Disorders Center
Thomas E. Schlaepfer, M.D.
Head, Division of Interventional Biological Psychiatry, Department of Psychiatry and
Psychotherapy Medical Center, University of Freiburg Faculty of Medicine, University
of Freiburg, Germany; Associate Professor, The Johns Hopkins Hospital, Department
of Psychiatry and Behavioral Medicine, Baltimore, Maryland
Marianne Seney, Ph.D.
Assistant Professor, Translational Neuroscience Program, Department of Psychiatry,
University of Pittsburgh, Pittsburgh, Pennsylvania
Luca Sforzini, M.D.
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
David V. Sheehan, M.D., M.B.A.
Distinguished University Health Professor Emeritus, University of South Florida College of Medicine, Tampa, Florida
Richard C. Shelton, M.D.
Charles Byron Ireland Professor, Department of Psychiatry and Behavioral Neurobiology, School of Medicine, The University of Alabama at Birmingham
Manpreet K. Singh, M.D., M.S.
Associate Professor of Psychiatry and Behavioral Sciences and Director of the Stanford
Pediatric Mood Disorders Program and the Pediatric Emotion and Resilience Lab,
Stanford University, Stanford, California
David C. Steffens, M.D., M.H.S.
Professor and Chairman, Department of Psychiatry, University of Connecticut School
of Medicine, Farmington, Connecticut
xxii The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Stephen M. Strakowski, M.D.
Vice Dean of Research and Associate Vice President of Regional Mental Health, Dell
Medical School, The University of Texas at Austin; Professor of Psychiatry & Behav
ioral Sciences, Psychology, and Educational Psychology, University of Texas, Austin
Caroline Symcox, B.Sc.
Postbaccalaureate Research Assistant, Department of Psychology, The University of
Texas at Austin
Michael E. Thase, M.D.
Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania,
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsyl
vania
Martha C. Tompson, Ph.D.
Associate Professor, Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts
Marisa Toups, M.D.
Assistant Professor of Psychiatry, Dell Medical School, University of Texas at Austin
Philip S. Wang, M.D., Dr.P.H.
Chair and Chief of Psychiatry, Cambridge Health Alliance, and Professor of the Practice of Psychiatry, Harvard Medical School, Cambridge, Massachusetts
-
-
Frances Isabella Weston, B.Sc.
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
Daniel R. Wilson, M.D., Ph.D.
President Emeritus, Western University of Health Sciences, Pomona, California
Hans-Ulrich Wittchen, Ph.D.
Professor of Clinical Psychology and Psychotherapy, Department of Psychiatry and
Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
Tyler Wright, M.D., M.P.H.
Chief Resident Physician, University of Southern California, Los Angeles, California
Brian W. Wu, M.D., Ph.D.
Resident Physician, University of Southern California, Los Angeles, California
Zhixing Yao, M.D.
Psychiatry Resident, Department of Psychiatry and Health Behavior, Medical College
of Georgia, Augusta University, Augusta, Georgia
Lakshmi N. Yatham, M.B.B.S., FRCPC
Professor and Head, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
Shiwen Yuan, M.D.
Clinical Instructor, Department of Psychiatry and Human Behavior, Brown University,
Providence, Rhode Island
Contributors xxiii
https://t.me/med1917
Kristina F. Zdanys, M.D.
Associate Professor, Department of Psychiatry, University of Connecticut School of
Medicine, Farmington, Connecticut
Hannah N. Ziobrowski, Ph.D., M.P.H.
Research Associate, Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
Disclosure of Interests
The following contributors to this textbook have indicated a financial interest in or other affiliation with
a commercial supporter, manufacturer of a commercial product, and/or provider of a commercial service
as listed below:
Joan R. Asarnow, Ph.D. Dr. Asarnow has received grant funding and/or other support from
the National Institute of Mental Health, the Substance Abuse and Mental Health Services Ad
ministration, the American Foundation for Suicide Prevention, the Association for Child and
Adolescent Mental Health, the American Psychological Association, and the Society of Clinical Child and Adolescent Psychology. She has also served as a consultant on quality improvement interventions for depression and suicidal/self-harm behavior and on Data Safety and
Monitoring and noncommercial Advisory Boards/Expert Panels, as well as on the scientific
advisory board for the Klingenstein Third Generation Foundation.
Pierre Blier, M.D., Ph.D. Dr. Blier received honoraria for giving lectures and/or for participat-
ing in advisory boards and/or providing expert testimony for Allergan, Bristol Myers Squibb,
Janssen, Lundbeck/Otsuka, and Pfizer. He received research grants from the Canadian Insti
tute of Health Research, Canadian Biomarkers for Depression, and Ontario Brain Institute.
Linda L. Carpenter, M.D. Research Support: Affect Neuro (formerly Feelmore Labs), Janssen,
NeoSync, Neuronetics, and Nexstim; Consultant: Janssen, Magstim, and Nexstim.
W. Edward Craighead, Ph.D. Dr. Craighead is a board member of Hugarheill ehf, an Icelandic
company dedicated to the prevention of depression; receives book royalties from John Wiley
& Sons (Hoboken, NJ, USA); is supported by National Institutes of Health funding, the Mary
and John Brock Foundation, and the Fuqua Family Foundations; and is a consultant to the
George West Mental Health Foundation, a member of the Scientific Advisory Board (SAB) of
the Anxiety and Depression Association of America, and a member of the SAB for AIM for
Mental Health Foundation.
Charles DeBattista, M.D. Grant Support: Abbott, Biolite, Compass, and Jansen; Consultant:
Alkermes and Corcept Therapeutics.
Charles F. Gillespie, M.D., Ph.D. Consultant: Cohen Veterans Bioscience.
Benjamin Goldstein, M.D., Ph.D. Dr. Goldstein received grant or research support from the
Brain and Behavior Research Foundation, Brain Canada, the Canadian Institutes of Health
Research, the Heart & Stroke Foundation, the National Institute of Mental Health, the Ontario
Ministry of Research & Innovation, and the University of Toronto Department of Psychiatry.
Jennifer L. Hughes, Ph.D., M.P.H. Dr. Hughes receives royalties from Guilford Press for the
following book: Kennard BD, Hughes JL, Foxwell AF: CBT for Depression in Children and Ado-
lescents: A Guide to Relapse Prevention. New York, Guilford Press, 2016. Research studies that
contributed to the development of this treatment (and subsequent book) are presented in
Chapter 27 of the Textbook, and this book is cited.
Ronald C. Kessler, Ph.D. In the past 3 years, Dr. Kessler received support for his epidemiolog-
ical studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, and Takeda; and served on an advisory board for the
Johnson & Johnson Services Inc. Lake Nona Life Project. Dr. Kessler is a co-owner of DataStat
Inc., a market research firm that carries out healthcare research.
-
-
xxiv The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Brandon M. Kitay, M.D., Ph.D. In the last 12 months, Dr. Kitay has provided consulting ser-
vices to Janssen Pharmaceuticals and has also received salary support from Janssen Pharmaceuticals and Sage Therapeutics for the conduct of research administered through Yale
University and the Yale Depression Research Program. In addition, Dr. Kitay’s employer, Yale
University, has a financial relationship with Janssen Pharmaceuticals, and may in the future
receive financial benefits from this relationship. The University has put multiple measures in
place to mitigate this institutional conflict of interest. Questions about the details of these
measures should be directed to Yale University’s Conflict of Interest office.
Matthew Macaluso, D.O., DFAPA Dr. Macaluso has conducted clinical trials research as prin-
cipal investigator for the following pharmaceutical companies over the last 12 months: Acadia, Allergan, AssureRx, Eisai, Lundbeck, Janssen, Naurex/Aptinyx, Neurim, and Suven. All
clinical trial and study contracts were with and payments made to the Kansas University
Medical Center Research Institute, a research institute affiliated with Kansas University
School of Medicine–Wichita (KUSM-W).
J. John Mann, M.D. Dr. Mann receives royalties from the Research Foundation for Mental
Hygiene for commercial use of the Columbia–Suicide Severity Rating Scale (C-SSRS).
John C. Markowitz, M.D. Dr. Markowitz receives minor royalties for books related to inter-
personal psychotherapy from American Psychiatric Association Publishing, Basic Books, and
Oxford University Press.
William V. McCall, M.D., M.S. Research Support: Merck, MECTA, and Vistagen; Scientific Ad-
visory Board: Jazz Pharmaceuticals and Sage Therapeutics; Royalties: Wolters Kluwer Publish-
ing; Speakers Bureau: CME Outfitters; Consultant: Anthem Insurance.
William McDonald, M.D. Dr. McDonald has research contracts from the Stanley Foundation,
Soterix, Neuronetics, NeoSync, and Cervel Neurotherapeutics. He is an ad hoc member of
several National Institute of Mental Health and National Institute of Neurological Disorders
and Stroke study sections. He is a member of the American Psychiatric Association Council
on Research and Quality representing Electroconvulsive and Neuromodulation Therapies.
Dr. McDonald is compensated as the chair of the Data and Safety Monitoring Board for the
National Institute on Aging multicenter study. He receives royalties from Oxford University
Press from co-editing a book on the Clinical Guide to Transcranial Magnetic Stimulation in
the Treatment of Depression. He is a paid consultant for Signant Health. He holds an endowed chair funded by the JB Fuqua Foundation. He is an employee of Emory University
School of Medicine.
David J. Miklowitz, Ph.D. Dr. Miklowitz has received research funding from the National In-
stitute of Mental Health (grants MH093676, MH097007, and MH117200) and from the
Deutsch and Kayne Family Foundations, AIM for Mental Health, the Attias Foundation, the
Danny Alberts Foundation, and the Max Gray Foundation.
Charles B. Nemeroff, M.D., Ph.D. Research Grants: National Institutes of Health (NIH), Stan-
ley Medical Research Institute; Consultant: Bracket (Clintara), Fortress Biotech, Gerson Lehrman Group (GLG) Healthcare and Biomedical Council, Janssen Research and Development
LLC, Magstim Inc, Prismic Pharmaceuticals, Sumitomo Dainippon Pharma, Sunovion Phar
maceuticals Inc, Taisho Pharmaceutical Inc, Takeda, Total Pain Solutions (TPS), and Xhale;
Stock Holdings: Abbvie, OPKO Health Inc, Antares, Bracket Intermediate Holding Corp, Celgene, Network Life Sciences Inc, Seattle Genetics, and Xhale; Scientific Advisory Board: Ameri-
can Foundation for Suicide Prevention (AFSP), Anxiety Disorders Association of America
(ADAA), Bracket (Clintara), Brain and Behavior Research Foundation (BBRF) (formerly
named National Alliance for Research on Schizophrenia and Depression [NARSAD]), Laure
ate Institute for Brain Research Inc, RiverMend Health LLC, Skyland Trail, and Xhale;
ectors: ADAA, AFSP, and Gratitude America; Income or Equity ($10,000 or more): American
Dir
Psychiatric Publishing, Bracket (Clintara), CME Outfitters, Takeda, and Xhale; Patents: U.S.
6,375,990B1 (method and devices for transdermal delivery of lithium) and U.S. 7,148,027B2
(method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay).
Board of
-
-
Contributors xxv
https://t.me/med1917
D. Jeffrey Newport, M.D., M.S. Dr. Newport has received research support from Eli Lilly,
Glaxo Smith Kline (GSK), Janssen, the National Alliance for Research on Schizophrenia and
Depression, the National Institutes of Health, Takeda Pharmaceuticals, and Wyeth. He has
served on speakers' bureaus and/or received honoraria from AstraZeneca, Eli Lilly, GSK,
Pfizer, and Wyeth. He has served on advisory boards for GSK, Janssen, and Sage Therapeu
tics. He has never served as a consultant to any biomedical or pharmaceutical corporations.
Neither he nor his family members have ever held equity positions in biomedical or pharma
ceutical corporations.
Andrew A. Nierenberg, M.D. Consulting: Acadia Pharm, Eisai, Ginger, Merck, Myriad, and
Protogenics; Scientific Advisory Board: Alkermes, Jazz Pharma, Neuronetics, Otsuka, and
Sage Pharma; Honoraria: Sunovion and Neurostar.
Edward Nunes, M.D. Dr. Nunes has received grant funding from the National Institute on
Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.
Carmine Pariante, M.D., Ph.D., FRCPsych Prof. Pariante has received research funding from
Johnson & Johnson as part of a program of research on depression and inflammation, and re
search funding from the Medical Research Council (U.K.) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include
Johnson & Johnson, Glaxo Smith Kline, and H. Lundbeck.
Gerard Sanacora, M.D., Ph.D. In the last 12 months Dr. Sanacora has provided consulting
services to Allergan, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim International, Bristol-Myers Squibb, Celexio Biosciences, EMA Wellness, Epiodyne, Intra-Cellular Therapies, Janssen, Lundbeck, Minerva Pharmaceuticals, Navitor
Pharmaceuticals, Neurocrine Biosciences, NeuroRx, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis, Seelos Pharmaceuticals, and Vistagen Therapeutics. He has received funds for contracted research from Janssen Pharmaceuticals, Merck, and Usona
Institute. He is holds equity in Biohaven Pharmaceuticals and has received royalties from
Yale University paid from patent licenses with Biohaven Pharmaceuticals. In addition, he
holds shares in Biohaven Pharmaceuticals Holding Company and is a co-inventor on a pat
ent, “Glutamate agents in the treatment of mental disorders” (Patent number: 8778979), and
a U.S. Provisional Patent Application (No. 047162-7177P1 [00754]) filed on August 20, 2018,
by Yale University Office of Cooperative Research (OCR 7451 US01). Dr. Sanacora’s em
ployer, Yale University, has a financial relationship with Janssen Pharmaceuticals, and may
in the future receive financial benefits from this relationship. The University has put multiple
measures in place to mitigate this institutional conflict of interest. Questions about the details
of these measures should be directed to Yale University’s Conflict of Interest office.
Richard C. Shelton, M.D. Dr. Shelton’s institution has received grant support from Acadia
Pharmaceuticals, Agency for Healthcare Research and Quality, Alkermes, Allergan, Avanir
Pharmaceuticals, Cerecor, Genomind, Intracellular Therapies, Janssen Pharmaceutica, Myriad
Genetics, National Institute of Mental Health, Navitor Pharmaceuticals, NeuroRx, Novartis,
Otsuka Pharmaceuticals, Patient-Centered Outcomes Research Institute, Sage Therapeutics,
and Takeda Pharmaceuticals. Dr. Shelton has served as a consultant to Acadia Pharmaceuti
cals, Allergan, Cerecor, Janssen Pharmaceutica, MSI Methylation Sciences, Naurex, and
Takeda Pharmaceuticals.
Manpreet K. Singh, M.D., M.S. Dr. Singh receives research support from Stanford’s Maternal
Child Health Research Institute and Department of Psychiatry
tal Health, the National Institute on Aging, Johnson & Johnson, Allergan, PCori, and the Brain
and Behavior Foundation. She is on the advisory board for Sunovion and is a consultant for
Google X and Limbix.
David C. Steffens, M.D., M.H.S. Consultant: Janssen Research and Development.
Michael E. Thase, M.D. Dr. Thase reports the following relationships over the past 3 years:
Advisor/Consultant: Acadia, Akili, Alkermes, Allergan (Forest, Naurex), Axsome Therapeutics, Boehringer-Ingelheim, Calla, Clexio Biosciences, H. Lundbeck, Jazz Pharmaceuticals,
Janssen (Johnson & Johnson), Otsuka, Perception Neuroscience, Sage Therapeutics, Seelos
, the National Institute of Men-
-
-
-
-
-
-
xxvi The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Pharmaceuticals, and Takeda; Grant Support: Acadia, Allergan (Forest, Naurex), Axsome
Therapeutics, Intracellular, Janssen Pharmaceutica (Johnson & Johnson), Myriad (Assurex),
Otsuka, and Takeda; Royalties: American Psychiatric Association Publishing, Guilford Publi
cations, Herald House, and W.W. Norton. Spouse’s Employment: Peloton Advantage, which
does business with a number of pharmaceutical companies. Disclosure of Intellectual Conflicts
of Interest (all prior to 2012): paid consultant to Depression Guideline Panel, Agency for Health
Care Policy and Research; unpaid consultant to Canadian Mood and Anxiety Treatment
Guidelines (1st & 2nd Editions) and American Psychiatric Association (DSM-III-R, DSM-IV,
and DSM-5); unpaid Work Group member, American Psychiatric Association Practice Guideline for Treatment of Patients With Bipolar Disorder (2nd Edition and, from 2006–2010, work
in preparation of 3rd Edition) and American Psychiatric Association Practice Guideline for
Treatment of Patients with Major Depressive Disorder (3rd Edition).
Martha C. Tompson, Ph.D. Dr. Tompson received research support from the National Insti-
tute of Mental Health, the Patient Centered Outcomes Research Institute, and the Smith Family Foundation; book royalties from Guilford Press and BVT Publishing; and honoraria from
the American Psychological Association.
Lakshmi N. Yatham, M.B.B.S., FRCPC Dr. Yatham has received research grants from or has
been a consultant or on speaker ⁄ advisory boards for Allergan, AstraZeneca, Alkermes, Bris
tol Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and
Anxiety Treatments, Dainippon Sumitomo, Eli Lilly, Forrest, Glaxo Smith Kline, Janssen,
Lundbeck, Michael Smith Foundation for Health Research, Novartis, Otsuka, Pfizer, Ranbaxy,
Servier, Sunovion, Teva, the Stanley Foundation, and Valeant Pharmaceuticals.
The following contributors stated that they had no competing interests during the year pre-
ceding manuscript submission:
Jorge Renner Cardoso de Almeida, M.D., Ph.D.; Yuanhan Bai, M.D., M.S.; Michelle A. Bertocci, Ph.D.; Joseph R. Calabrese, M.D.; Frances A. Champagne, Ph.D.; Adora Choquette,
B.A.; Samuel J. Collier, M.D.; William Coryell, M.D.; Adel Farah, M.D., M.Sc.; Andrew A.
Fukuda, M.D., Ph.D.; Keming Gao, M.D., Ph.D.; Ana Gomez-Carrillo, M.D.; Ilang M.
Guiroy, M.D.; G. Eric Jarvis, M.D., M.Sc.; Brian C. Kavanaugh, Psy.D.; Laurence J. Kirmayer,
M.D.; Teresa Lanza di Scalea, M.D., Ph.D.; David A. Lewis, M.D.; Elizabeth T. C. Lippard,
Ph.D.; Dean F. MacKinnon, M.D.; Melissa P.H. Miller, M.Sc.; Trevor Mooney, M.D.; Alison
Myoraku, M.S.; Maria Antoinetta Nettis, M.D., Ph.D.; Lisa O’Donnell, Ph.D.; Dan A. Oren,
M.D.; Vanessa Padilla, M.D.; Brenda W. J. H. Penninx, M.D., Ph.D.; Grazyna Rajkowska,
Ph.D.; Mina M. Rizk, M.B.B.Ch., M.Sc.; Mitchell Rovner, M.D.; James K. Rustad, M.D.; Marianne Seney, Ph.D.; Luca Sforzini, M.D.; Marisa Toups, M.D.; Philip S. Wang, M.D., Dr.P.H.;
Daniel R. Wilson, M.D., Ph.D.; Hans-Ulrich Wittchen, Ph.D.; Tyler Wright, M.D., M.P.H.;
Zhixing Yao, M.D.; Shiwen Yuan, M.D.; Kristina F. Zdanys, M.D.; Hannah N. Ziobrowski,
Ph.D., M.P.H.
-
-
Acknowledgments
https://t.me/med1917
Dr. Nemeroff would like to acknowledge Kelly Puzdrak for getting this volume put
together and for everything else as well.
Dr. Rasgon would like to acknowledge Alison Myoraku, M.S., for her contributions.
Dr. Schatzberg would like to acknowledge Adrienne Bronfeld for her contributions.
Dr. Strakowski would like to acknowledge Chiara Onyett and Alison Barajas for their
contributions.
xxvii
https://t.me/med1917
PART I
https://t.me/med1917
Symptomatology and Epidemiology
Соседние файлы в папке Библиотека им академика М.И. Перельмана